Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
| dc.contributor.author | Yao, J | |
| dc.contributor.author | Fazio, N | |
| dc.contributor.author | Singh, S | |
| dc.contributor.author | Buzzoni, R | |
| dc.contributor.author | Carnaghi, C | |
| dc.contributor.author | Wolin, E | |
| dc.contributor.author | Tomasek, J | |
| dc.contributor.author | Raderer, M | |
| dc.contributor.author | Lahner, H | |
| dc.contributor.author | Voi, M | |
| dc.contributor.author | Pacaud, L | |
| dc.contributor.author | Rouyrre, N | |
| dc.contributor.author | Sachs, C | |
| dc.contributor.author | Valle, Juan W | |
| dc.contributor.author | Fave, G | |
| dc.contributor.author | Van Cutsem, E | |
| dc.contributor.author | Tesselaar, M | |
| dc.contributor.author | Shimada, Y | |
| dc.contributor.author | Oh, D | |
| dc.contributor.author | Strosberg, J | |
| dc.contributor.author | Kulke, M | |
| dc.contributor.author | Pavel, M | |
| dc.date.accessioned | 2016-02-04T09:23:45Z | en |
| dc.date.available | 2016-02-04T09:23:45Z | en |
| dc.date.issued | 2015-12-15 | en |
| dc.identifier.citation | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. 2015: Lancet | en |
| dc.identifier.issn | 1474-547X | en |
| dc.identifier.pmid | 26703889 | en |
| dc.identifier.doi | 10.1016/S0140-6736(15)00817-X | en |
| dc.identifier.uri | http://hdl.handle.net/10541/595567 | en |
| dc.description.abstract | Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. | |
| dc.language | ENG | en |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Lancet (London, England) | en |
| dc.title | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. | en |
| dc.type | Article | en |
| dc.contributor.department | University of Texas MD Anderson Cancer Center, Houston, TX | en |
| dc.identifier.journal | Lancet | en |
| html.description.abstract | Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. |